Risk factors for self-reported colon polyps

Kahn, Henry S.; Tatham, Lilith; Thun, Michael J.; Heath, Clark W.

doi:10.1046/j.1525-1497.1998.00095.x

Cited by 39 publications

(33 citation statements)

References 50 publications

(74 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A possible target of the cancer chemopreventive effect of non-steroidal anti-inflammatory drugs (NSAIDs) is the inhibition of cyclooxygenase (COX), the enzymes responsible for the synthesis of prostaglandins. The evidence of a protective role of aspirin and other NSAIDs on the risk of colorectal cancer had been stimulated by epidemiological observations [4][5][6][7][8][9][10], with the pooled odds ratio (OR) 0.87 (95% confidence intervals [CI]: 0.77-0.98) in case-control studies and relative risk (RR) 0.72 (95% CI: 0.61-0.85) in cohort studies [11]. The same protective role of aspirin was also observed in esophageal and gastric cancer with pooled RR of 0.51 (95% CI: 0.38-0.69) and 0.73 (95% CI: 0.63-0.84), respectively [12].…”

Section: Introductionmentioning

confidence: 99%

Association between NSAIDs use and breast cancer risk: a systematic review and meta-analysis

Zhao

Zhu

et al. 2008

Breast Cancer Res Treat

View full text Add to dashboard Cite

The association between non-steroidal anti-inflammatory drugs (NSAIDs) use and breast cancer has remained controversial. Therefore, an overall quantitative estimate of the association needs to be studied. A systematic review and meta-analysis was executed to explore the pooled estimate for relative risk (RR) and 95% confidence interval (CI) using random or fixed effects models based on heterogeneity analysis. Overall 26 studies with 528,705 participants were included. The RR of NSAIDs use and the incidence of breast cancer was 0.94 (95% CI: 0.88-1.00) with random effects model. A slight reduction of breast cancer by taking aspirin and ibuprofen was both observed with pooled RR of 0.91 (95% CI: 0.83-0.98) and 0.81 (95% CI: 0.67-0.97), respectively. Our results indicate that NSAIDs use is associated with a slight decrease for the development of breast cancer with a marginally statistical significant difference. The associations are slightly more obvious in aspirin and ibuprofen use.

show abstract

Section: Introductionmentioning

confidence: 99%

Association between NSAIDs use and breast cancer risk: a systematic review and meta-analysis

Zhao

Zhu

et al. 2008

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…Two studies [11,23] analyzed only advanced adenomas excluding small or non-multiple adenomatous polyps. The countries in which studies had been conducted were Germany (n = 1) [6], Japan (n = 4) [7,9,18,25], South Korea (n = 4) [8,12,13,23], Taiwan (n = 1) [10], the United States (n = 12) [11,14,15,17,21,22,24,[26][27][28][29][30], Denmark (n = 1) [16], Norway (n = 1) [19], and France (n = 1) [20]. Six studies [15,17,18,21,23,25] had hospital-based case-control designs.…”

Section: Selection Of Studiesmentioning

confidence: 99%

“…Six studies [15,17,18,21,23,25] had hospital-based case-control designs. Five [16,19,20,22,24] were population-based case-control studies, and all the cohort studies [26][27][28][29][30] were prospectively designed and conducted in the United States.…”

Section: Selection Of Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Adiposity and the risk of colorectal adenomatous polyps: a meta-analysis

Lee

Myung

Cho

et al. 2011

Cancer Causes Control

View full text Add to dashboard Cite

show abstract

“…Twelve case-control studies assessed the association between aspirin use and colorectal polyps [86][87][88][89][90][91][92][93][94][95][96][97][98]. Eighteen case-control studies evaluated the effect of aspirin or NSAIDs on the risk of colorectal carcinoma [99][100][101][102][103][104][105][106][107][108][109][110][111][112][113][114][115].…”

Section: Case-control Studiesmentioning

confidence: 99%

Low Dose Aspirin, COX-Inhibition and Chemoprevention of Colorectal Cancer

Bénamouzig¹,

Uzzan²,

Little³

et al. 2005

CTMC

View full text Add to dashboard Cite

Chemoprevention of colorectal cancer involves the long-term use of pharmacologic agents that can prevent neoplasms from developing in the large bowel. This new approach requires major funding and human investments. Among the most widely studied agents for the chemoprevention of colorectal cancer, aspirin, the NSAIDs and COX-2 inhibitors seem to be the most promising. A large number of observational epidemiological studies show that regular use of aspirin and other NSAIDs is associated with a reduction in the risk of developing both colorectal adenomas and cancer. In addition, the prodrug sulindac reduces the growth of existing polyps in familial adenomatous polyposis (FAP). However, the dose, duration of effect and length of protection seen after cessation remain to be fully established. Furthermore, in view of previous discrepancies between the results of observational studies and randomized control trials (RCTs), it is crucially important to investigate the effects of aspirin by RCTs. RCTs investigating the effect of chemopreventive agents on adenoma recurrence as an intermediate endpoint for colorectal cancer is a more feasible approach than RCTs to investigate the effect on the incidence if colorectal cancer per se. Four RCTs of the effect of aspirin on adenoma recurrence are available. Other trials are currently underway.

show abstract

Risk factors for self-reported colon polyps

Cited by 39 publications

References 50 publications

Association between NSAIDs use and breast cancer risk: a systematic review and meta-analysis

Association between NSAIDs use and breast cancer risk: a systematic review and meta-analysis

Adiposity and the risk of colorectal adenomatous polyps: a meta-analysis

Low Dose Aspirin, COX-Inhibition and Chemoprevention of Colorectal Cancer

Contact Info

Product

Resources

About